Diane Prager

发表

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

Xin Li, Roy S Herbst, Hai T Tran, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

David Cella, Karen Kelly, Roy S Herbst, 2003, JAMA.